research Studying Cytotoxic T-Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Polymorphism in a Sample of Iraqi Women with Polycystic Ovarian Syndrome
The CTLA-4 gene change studied does not affect Polycystic Ovarian Syndrome in the women tested.
Search
for
Sort by
Research
30 / 1000+ results 
research The Role of Lymphocytes in the Development and Treatment of Alopecia Areata
Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.
research Cutaneous Manifestations Associated With Immune Checkpoint Inhibitors
Immune checkpoint inhibitors can cause skin issues but are linked to better cancer outcomes.
research Regulatory T Cells in Autoimmune Skin Diseases
Treg dysfunction is linked to various autoimmune skin diseases, and understanding Treg properties is key for new treatments.
research CTLA4 +49AG (rs231775) And CT60 (rs3087243) Gene Variants Are Not Associated With Alopecia Areata In A Mexican Population From Monterrey, Mexico
CTLA4 gene variants are not linked to alopecia areata in Monterrey's Mexican population.
research Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity
Alopecia areata involves both innate and adaptive immunity, with specific genes linked to the disease.
research Genome-Wide Association Study of Alopecia Areata in Taiwan: The Conflict Between Individuals and Hair Follicles
Certain genetic variants linked to immune response increase the risk of alopecia areata in Taiwanese people.
research Alopecia Areata: An Autoimmune Disease Causing Hair Loss
Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.
research Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences
Alopecia areata and vitiligo share immune system dysfunction but differ in specific immune responses and affected areas.
research Alopecia Areata: A Review of Disease Pathogenesis
Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.
research Regulatory T Cells: The Many Faces of Foxp3
Foxp3 is crucial for regulatory T cell function, and targeting these cells may help treat immune disorders.
research Imbalance of T-Helper 17 and Regulatory T Cells in Patients with Alopecia Areata
People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.
research A Novel Therapeutic Paradigm for Patients with Extensive Alopecia Areata
New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
research MicroRNA in Skin Diseases
Certain microRNAs are linked to various skin diseases and could be used to diagnose and treat these conditions.
research Alopecia Areata: A Comprehensive Review of Pathogenesis and Management
New treatments for Alopecia Areata show promise but need to be more effective and affordable.
research Alopecia
The document concludes that alopecia has significant social and psychological effects, leading to a market for hair loss treatments.
research Tregs: Where We Are and What Comes Next?
The conclusion is that Treg-targeted therapies have potential, but more knowledge of Treg biology is needed for effective treatments, including for cancer.
research Analysis of CTLA-4 Gene +49A/G and CT60 A/G Polymorphisms in Alopecia Areata Patients
CT60 polymorphism might increase the risk of Alopecia Areata.
research Medications
Understanding drug interactions, side effects, and patient-specific factors is crucial for effective dermatological care.
research Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.
research Foxp3 Post-Translational Modifications and Treg Suppressive Activity
Changes to the Foxp3 protein affect how well regulatory T cells can control the immune system, which could help treat immune diseases and cancer.
research Prevention And Management Of Dermatological Toxicities Related To Anticancer Agents: ESMO Clinical Practice Guidelines
Early intervention and tailored management can reduce skin side effects from cancer treatments.
research Understanding, Recognizing, and Managing Toxicities of Targeted Anticancer Therapies
Targeted anticancer therapies can cause severe side effects similar to traditional chemotherapy, but with different types.
research Cytokine-Targeted Treatment in Alopecia Areata - New Possibilities?
New cytokine-targeted therapies show promise for treating alopecia areata.
research Alopecia Areata: Chronic Inflammatory Skin Disorder
The document says a skin condition called alopecia areata causes hair loss and stress, and is treated with strong skin creams, injections, or other therapies, but treatment success varies.
research Drug Pipeline Q2 2022: A Downturn in Approvals
Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
research Epidemiology and Burden of Alopecia Areata: A Systematic Review
Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.
research Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata
Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.
research Association Between Interleukin 18 Polymorphisms and Alopecia Areata in Koreans
Certain genetic variations in IL18 may increase the risk of alopecia areata in Koreans.
research The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: The Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.